The tweet was deleted by the author.
But we saved everything 🙂.
Cullinan Therapeutics reported its corporate update and financial results for the second quarter of 2026, sharing details on business performance and developments in its T cell engager pipeline.
The company outlined upcoming operational milestones and growth initiatives, encouraging stakeholders to review additional information through its latest presentation.
View post on X Loading...
Earlier this year, Cullinan Therapeutics advanced its CLN-049 therapy to Phase 2 for relapsed and refractory AML following positive FDA feedback, according to company disclosures. The company has also supported LGBTQIA biotech professionals through sponsorship of the OUTbio Boston event, as noted in previous reports. These efforts reflect Cullinan's continued activity on pipeline development and industry engagement.